TET2 and myelodysplastic syndrome: Thus, in addition to providing BM radiation resistance, CR or CR mimetics may provide an advantage for non-cancerous TET2 WT BM HSPCs to compete against enzyme inactive TET2 mutant HSPCs, potentially limiting aplastic anemia and/or myelodysplastic syndromes.